AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06363994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orelabrutinib
Description: Eligible patients will receive Orelabrutinib orally as per the protocol，until disease progression or other reasons for treatment discontinuation，whichever comes first.
Study NCT06363994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine Injection
Description: Eligible patients will receive Bendamustine by injection as per the protocol
Study NCT06363994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Eligible patients will receive Rituximab by injection as per the protocol
Study NCT06363994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orelabrutinib Placebo
Description: Eligible patients will receive Orelabrutinib Placebo orally as per the protocol
Study NCT04631601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acapatamab
Description: Acapatamab will be administered as an intravenous (IV) infusion.
Study NCT04631601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide will be administered orally.
Study NCT04631601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Abiraterone will be administered orally.
Study NCT04631601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 404
Description: AMG 404 will be administered as an intravenous (IV) infusion.
Study NCT04631601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 404
Description: AMG 404 will be administered as an intravenous (IV) infusion.
Study NCT06569199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Bracing
Description: Premade fabricated braces in three sizes (small, medium and large) that have been designed for the pediatric age group between 0-5 years old will be stocked at the Alberta Children's Hospital. Braces will be applied to participants in the emergency department. As these braces are designed to allow for positional adjustments, if deemed necessary adjustments will be made by the attending orthopaedic surgeon at subsequent follow-up visit(s).
Study NCT06569199 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hip Spica Cast
Description: The current standard of care for diaphyseal pediatric hip fractures in children aged 6 months to 5 years old is hip spica casting. A hip spica is a hard cast that covers a child's body from the chest down to their knees or ankles allowing for fracture immobilization to promote healing. Application of the spica cast occurs in the operating room and requires a general anaesthetic. Caring for a child in a hip spica cast presents significant challenges for caregivers due to the cast's cumbersome size and restricted mobility which makes routine caregiver activities like daily hygiene, toileting, transportation and skin surveillance difficult. Inadequate maintenance of the spica cast may result in skin complications, necessitating extra visits for cast adjustments, or potentially requiring revision casting in the operating room.
Study NCT05709574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 MG
Description: Tadalafil 20 mg tablets will be taken daily for 2 weeks alone and then for 8 weeks in combination with neoadjuvant chemotherapy in the window between gastric/GEJ adenocarcinoma diagnosis and interventional surgery.
Study NCT06041724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab combined with recombinant human endostatin and first-line chemotherapy
Description: Envafolimab: 300mg day1, s.c. Q3W; Recombinant human endostatin: 210mg day1, Intravenous pump for 72 hours, Q3W; Temozolomide: 150 mg/m2 d1-5, i.v. Q3W; Cisplatin: 25 mg/m2 d1-3, i.v. Q3W.~All of the above drugs were used for 6 cycles, and then Envafolimab and recombinant human endostatin continued only in patients with no progression in the first stage until disease progression as defined by RECIST1.1, unacceptable toxicity, withdrawal from the study or death, or no more than 2 years.
Study NCT04997174 — intervention group
Intervention type: DRUG
Intervention: Celecoxib
Description: Patients in ERAS group received celecoxib
Study NCT05430490 — intervention group
Intervention type: PROCEDURE
Intervention: MRI
Description: Multimodal neuroimaging on 3T Prisma Fit MRI
Study NCT05430490 — intervention group
Intervention type: OTHER
Intervention: NeuroPsychological Testing
Description: A series of written, verbal, and motor tasks requiring the participant to follow instructions, remember words and numbers, draw objects, and complete timed actions.
Study NCT05430490 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Laboratory reports (CMP, CBC, Lipids)
Study NCT05430490 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Life history, current behaviors, and substance use surveys
Study NCT05430490 — intervention group
Intervention type: PROCEDURE
Intervention: Lumbar Puncture
Description: Optional procedure which involves obtaining cerebral spinal fluid through a needle in the lower back
Study NCT05689346 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high tone power therapy
Description: high tone power therapy
Study NCT05689346 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional physical therapy exercises
Description: traditional physical therapy exercises for improving balance
Study NCT05500885 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEMF device, Quantum Tx, Singapore
Description: The options of the appliance will be adjusted to 1.5mT, 10Hz on the diseased leg for 10 minutes.
Study NCT05500885 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard rehabilitation and sham PEMF therapy for CAI
Description: Balance training and muscle strengthening
Study NCT06302556 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Immune checkpoints analysis
Description: The researcher will analyze immune checkpoint molecules, which will include the lymphocyte activation gene-3 (LAG-3), T cell immunoglobulin and mucin-domain containing-3 (TIM-3), V-domain Ig suppressor of T cell activation (VISTA), besides the canonical PD1 and ligands L1 and L2, T cell immunoglobulin and ITIM domain (TIGIT) and CTLA-4. In addition, Foxp3, GATA3 and TOX will be analyzed as specific lineage markers.
Study NCT06302556 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Gene expression analysis
Description: Immune cells will be purified from bronchoalveolar lavage; total RNA will be purified and subjected to gene expression analysis by Quantigene multiplex 80-plex Assay, which allows to evaluate simultaneously the follow mRNA targets: CCL2, CCL3, CCL5, CXCL10, CSF2, CSF3, IL1A, IL1B, IL1RN, IL6, IL6R, IL8, IL10, IL12B, IL17A, IL18, IL22, IL28A, TNF, TNFRSF4, IFNA2, IFNB1, IFNG, IFI16, IFITM1, IFITM3, MX1, TLR3, TLR4, TLR7, TLR8, NOD1, NOD2, CASP1, NLRP3, PYCARD, CD44, CLEC4M, CD209, ITGA4, ITGB7, CH25H, ABCA1, HMGCS1, NR1H3, ACAT1, PDCD1, PTGS2, CD274, CD69, MPO, HAVCR2, TAP1, ERAP1, ERAP2, AGTR2, AGTR1, PPARG, CRP, IL7, IL12A, ACE2, ELOVL6, CD38, NOS2
Study NCT05893940 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low Intensity Vibration Therapy
Description: Undergo LIMS vibration therapy
Study NCT05893940 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual X-ray Absorptiometry
Description: Undergo DEXA scan
Study NCT05893940 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT05668416 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education
Description: The training includes brochures and oral training prepared by the researchers in line with the literature and the training given in the hospital. Education brochure (Day surgery training brochure); An educational brochure was prepared by the researchers in line with the literature and practices in the institution. The brochure was composed of 3 sections: pre-operative, on the day of the operation and after the operation.
Study NCT05434156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELE-101
Description: ELE-101 solution for intravenous infusion
Study NCT05434156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELE-101 Placebo
Description: ELE-101 placebo matching solution for intravenous infusion
Study NCT06067906 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hypocaloric diet
Description: Hypocaloric diet
Study NCT06067906 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dissociated diet
Description: Dissociated diet
Study NCT05017675 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fructose diet
Description: 4 week high fructose diet.~Intended composition (En%):~Carbohydrates: 60-70 Fat: 20-30 Protein: 10-15 Fructose: 20 SFA: 5
Study NCT05017675 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High saturated fat diet
Description: 4 week high saturated fat diet.~Intended composition (En%):~Carbohydrates: 35-45 Fat: 40-50 Protein: 10-15 Fructose: 5 SFA: 20
Study NCT06577688 — intervention group
Intervention type: OTHER
Intervention: Blood pressure measurement
Description: Blood pressure measurement using a standard cuff device and a smartphone
Study NCT06578520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 10 mg once per day, oral tablets
Study NCT06575283 — intervention group
Intervention type: OTHER
Intervention: No intervention will be performed in this cohort study
Description: Deep learning classification models will be used for automatic prediction of cerebral palsy. Machines will be used to assist doctors in cerebral palsy risk evaluation.
Study NCT06574646 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LAL+
Description: LAL+ IOL allows for refractive error (both sphere and cylinder) enhancements post-IOL implantation by exposing the IOL to ultraviolet (UV) light through a series of noninvasive treatments with a Light Delivery Device.
Study NCT06574646 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clareon Vivity Toric IOL
Description: Clareon Vivity Toric IOL utilizes an extended depth of focus (EDOF) design, which incorporates nondiffractive wavefront shaping (X-WAVE) technology.
Study NCT06497530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: Serplulimab will be administered intravenously at a dose of 4.5 mg/kg on Day 1 of each 21-day cycle for 4 cycles in the induction phase.~Serplulimab will be administered intravenously at a dose of 4.5 mg/kg on Day 1 of each 21-day cycle in the maintenance phase.
Study NCT06497530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Lurbinectedin will be administered intravenously at a fixed dose of 4 mg on Day 1 of each 21-day cycle in the maintenance phase.
Study NCT06497530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered according to the standard of care treatment for 4 cycles in the induction phase.
Study NCT06497530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide will be administered according to the standard of care treatment for 4 cycles in the induction phase.
Study NCT04823273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General improvement
Description: Changes to interface to be more intuitive.
Study NCT04823273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-line help text
Description: General improvement + in-line help text
Study NCT04823273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interruptive alert
Description: General improvement + interruptive alert
Study NCT04957966 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-selected relaxing music
Description: 20 minutes music listening
Study NCT06320509 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Continuous measurement of uPO2 (both groups)
Description: uPO2 is collected continuously for the first 5 days of admission or until discharge from intensive care or removal of the urinary catheter.
Study NCT06001710 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Needleless jet injector
Description: Device consist of injection pen, ampule and activator.
Study NCT06580626 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: decompression technique
Description: 14 implants will be placed in patients of missing single tooth or multiple teeth in posterior mandible with subsequent horizontal ridge augmentation by decompression technique.
Study NCT06580626 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: guided bone regenaration using Ethoss
Description: 14 implants will be placed in patients of missing single tooth or multiple teeth in posterior mandible with subsequent horizontal ridge augmentation by guided bone regeneration using β-TCP/CS synthetic bone substitute.
Study NCT06580626 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ridge splitting technqiue
Description: 14 implants will be placed in patients of missing single tooth or multiple teeth in posterior mandible with subsequent horizontal ridge augmentation by ridge splitting technique using piezosurgery.
Study NCT06341179 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep extension
Description: Children and their parents will receive a behavioral intervention consisting of two in-person sessions and four virtual sessions. The two in-person sessions will take place at the beginning of the study (during weeks 1 and 2) and will focus on effective behavioral strategies to enhance sleep time, including goal setting (e.g., bedtimes and wake-up times), self-monitoring (via actigraphy), problem-solving and preplanning, stimulus control (i.e., sleep hygiene recommendations), and positive reinforcement. The four virtual sessions will take place at frequent intervals during the 12-week intervention (at weeks 4, 6, 8, and 10) and will act as reminders/refreshers to reinforce strategies to enhance changes in sleep time. Parents will receive advice in relation to altering only their children's sleeping routine (bedtime), and they will be instructed not to directly modify their children's food consumption or physical and sedentary activities during daytime.
Study NCT05078190 — intervention group
Intervention type: OTHER
Intervention: Social Determinants of Health
Description: The study will perform detailed phenotyping of Social Determinants of Health using the National Institute of Minority Health and Health Disparities PhenX SDOH toolkit at baseline.
Study NCT04910269 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)
Description: The hIVIG product is administered as a single dose of 3.5 grams, or 35 milliliter at a concentration of 0.1 grams/milliliter.
Study NCT04910269 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infusion of 35 milliliters standard isotonic saline
Study NCT05735873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-energy diet
Description: Twenty-one pre-made, low-energy meals delivered weekly to the subject for 12 weeks.
Study NCT05745077 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine Consultation
Description: Patients will be contacted by their surgeon over the phone to discuss surgical treatment.
Study NCT05745077 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Care
Description: Patients will proceed with their surgical consultation as per standard practice.
Study NCT04976738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cybis™ 10:25 THC:CBD oil
Description: Cybis™ 10:25 containing 10 mg/mL of D9-THC and 25 mg/mL of CBD, formulated in medium chain triglycerides (MCT)
Study NCT06370767 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bike-Share Travel Training
Description: Half of the participants not assigned to the waitlist will begin the bike-share intervention arm immediately after the baseline research interview. The bike-share arm will last for 8 weeks and be delivered by a community peer specialist. Half of the participants assigned to the waitlist will begin the bike-share intervention arm after an 8-week waiting period.
Study NCT06370767 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Public Transportation Travel Training
Description: Half of the participants not assigned to the waitlist or bike-share arm will begin the public transportation intervention arm immediately after the baseline research interview. The public transportation arm will last for 8 weeks and be delivered by a community peer specialist. Half of the participants assigned to the waitlist will begin the public transportation intervention arm after an 8-week waiting period.
Study NCT05579860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olezarsen
Description: Olezarsen will be administered by SC injection.
Study NCT04919083 — intervention group
Intervention type: OTHER
Intervention: Program of Therapeutic Exercise and Functional Recovery
Description: Specific hip fracture recovery programme,restoring the mobility, strength and balance of the operated patient, in order to facilitate the return to a functional state as close as possible to the state prior to surgery and in the shortest possible time, as detailed in Annex VIII. This programme is part of the standard treatment protocol implemented since January 2021 by the Orthogeriatrics Unit of the San Juan de Dios Hospital.~This programme is divided into 5 phases, each of these phases coincides with a level of the gait assessment scale. Each individual will start at the level assigned by the doctor and will only have access to the videos of the indicated level and the levels below it. As the patient meets the recovery goals, the physician will provide access to the higher level videos.The functional recovery plan begins the day after the hip fracture and continues after the patient has been discharged for a total of 16 weeks.
Study NCT04919083 — intervention group
Intervention type: OTHER
Intervention: Standardised nursing care plan
Description: Consisting of postural changes described in the standardised nursing care plan. Within this plan, the patient was moved to a sitting position prematurely (within the first 24 hours) and started to ambulate within the following 48 hours, provided that the patient's general condition allowed it. This group did not receive any specific functional recovery plan.
Study NCT06001710 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needleless jet injector
Description: Device consist of injection pen, ampule and activator.
Study NCT06574477 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Planning of alignment with HoloLens 2
Description: Planning of attachment position and traction direction with HoloLens 2 goggles
Study NCT06574477 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No planning of alignment with HoloLens 2
Description: No planning of attachment position and traction direction with HoloLens 2 goggles
Study NCT06576453 — intervention group
Intervention type: BEHAVIORAL
Intervention: Self-questionnaire WHOQOL-bref
Description: Parents must complete the self-questionnaire WHOQOL-bref after the first and the last session of the Pepps program.
Study NCT05124691 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Albendazole and Ivermectin fixed dose coformulation
Description: 400 mg Albendazole - 9 mg Ivermectin OR 400 mg Albendazole - 18 mg Ivermectin
Study NCT06576453 — intervention group
Intervention type: BEHAVIORAL
Intervention: Self-questionnaire Evaluation Inventory - Parent
Description: Parents must complete the self-questionnaire Evaluation Inventory - Parent after the last session of the Pepps program.
Study NCT06276192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Physiotherapy (diSAID)
Description: The diSAID is developed by the research group and is a modified version of a previously tested exercise program for patients with subacromial pain. The diSAID is distributed in three stages with; Information about subacromial pain, effects of exercise, pain management and ergonomics in everyday living and at work. The training includes exercises for the rotator cuff and scapular stabilizers as well as posterior shoulder stretch. The exercises are performed 1 time/day during twelve weeks with a progression of dose, load and complexity continuously. Pain while performing the exercise program is accepted up until NRS 5 out of 10.~During ongoing treatment, there is the opportunity for counselling, individualization of exercises, adjustment of dose and load based on stated instructions from the treating physiotherapist.~Adherence, levels of pain and function is reported continuously by the patient via the digital platform.
Study NCT06276192 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Physiotherapy
Description: Patients in the active control group are offered the usual treatment practice that is currently offered by physiotherapists in primary care. No predetermined directives for the active control group are defined prior to the study and can contain; home exercise programs, manual therapy and other techniques. The treating physiotherapists in this group are not involved in the digital treatment. The choice of interventions, amounts of visits and adherence is checked retrospectively via patient data and medical records.
Study NCT06155968 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: QL block
Description: The curvilinear probe (2 5 MHz, SonoSite Turbo M) is placed in the transverse axial plane just cranial to the iliac crest. The shamrock sign was visualised (viz., the transverse process (TP) of vertebra L4 is the stem, whereas the erector spinae muscle (ESM) posteriorly, quadratus lumborum (QL) muscle laterally and the psoas major (PM) muscle anteriorly represent the three leaves). The needle is introduced using an in plane technique from the posterior end of the transducer through the QL muscle. The target for injection is the fascial plane between the QL and PM muscles..